TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36780768

Group type: EXPERIMENTAL
Intervention: Overdose Education and Naloxone Distribution (OEND) strategies
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Medication Treatment for Opioid Use Disorder (MOUD) strategies
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Safer Prescribing and Dispensing Practices (SPDP) strategies
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Overall strategy selection
Number of subjects: 33

Group type: COMPARATOR
Intervention: OEND and MOUD strategy selection
Number of subjects: 33
Study: 36780810

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM) training
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control training
Number of subjects: 76
Study: 36780943

Group type: EXPERIMENTAL
Intervention: High dairy protein + walking exercise
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study: 36781102

Group type: EXPERIMENTAL
Intervention: benralizumab
Number of subjects: 29
Study: 36781156

Group type: EXPERIMENTAL
Intervention: CNN2 model
Number of subjects: 170
Study: 36781334

Group type: EXPERIMENTAL
Intervention: SCB-2019 (two doses administered intramuscularly 21 days apart)
Number of subjects: 691

Group type: COMPARATOR
Intervention: SCB-2019 (one dose administered)
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: SCB-2019
Number of subjects: 691
Study: 36781422

Group type: EXPERIMENTAL
Intervention: Highest quartile of oxidative balance score (OBS)
Number of subjects: 18561
Study: 36781451

Group type: EXPERIMENTAL
Intervention: Pexiganan (NCT01594762, 2012-05-07)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omiganan (NCT02576847, 2015-10-13)
Number of subjects: 0
Study: 36781469

Group type: EXPERIMENTAL
Intervention: Pronase administration
Number of subjects: 955

Group type: COMPARATOR
Intervention: Control group (no pronase administration)
Number of subjects: 955
Study: 36781590

Group type: EXPERIMENTAL
Intervention: Immediate temporization (IT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CTG) with no temporization
Number of subjects: 20
Study: 36781617

Group type: EXPERIMENTAL
Intervention: Vibration training program (8 weeks, 3 sessions per week)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vibration training program
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (normal lifestyle)
Number of subjects: 48
Study: 36781774

Group type: EXPERIMENTAL
Intervention: Plerixafor-based hematopoietic cell mobilization combined with granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Plerixafor-based mobilization
Number of subjects: 23
Study: 36781928

Group type: EXPERIMENTAL
Intervention: Sarpogrelate plus aspirin (300 mg orally once per day for 6 months)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin (75 mg orally once per day for 6 months)
Number of subjects: 272
Study: 36782059

Group type: EXPERIMENTAL
Intervention: Patients with SCN4A variants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 36782093

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 787

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg and 400 mg
Number of subjects: 787
Study: 36782134

Group type: EXPERIMENTAL
Intervention: Colorectal cancer survivors' recollections of their illness and treatment experiences after therapy
Number of subjects: 96
Study: 36782227

Group type: EXPERIMENTAL
Intervention: 80% fraction of inspired oxygen (FiO2)
Number of subjects: 193

Group type: COMPARATOR
Intervention: 28% fraction of inspired oxygen (FiO2)
Number of subjects: 193
Study: 36782282

Group type: EXPERIMENTAL
Intervention: Computed tomography monitoring of bone mineral density (BMD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Age as a personal factor
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall BMD change across different foot bones
Number of subjects: 60
Study: 36782297

Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 1595

Group type: COMPARATOR
Intervention: Preconception
Number of subjects: 1595
Study: 36782301

Group type: EXPERIMENTAL
Intervention: ACCEPT decision intervention (ADI)
Number of subjects: 24
Study: 36782325

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (1500 mg once weekly for 8 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Oral azithromycin
Number of subjects: 68
Study: 36782326

Group type: EXPERIMENTAL
Intervention: Baseline ILA
Number of subjects: 1699
Study: 36785526

Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic therapy (ofloxacin or third-generation cephalosporin)
Number of subjects: 282

Group type: COMPARATOR
Intervention: 14 days of antibiotic therapy (ofloxacin or third-generation cephalosporin)
Number of subjects: 282
Study: 36785834

Group type: EXPERIMENTAL
Intervention: DeepInteg (multi-task deep learning tool)
Number of subjects: 1700
Study: 36785850

Group type: EXPERIMENTAL
Intervention: 3+1 PCV10 schedule (2,3,4,9 months)
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: 3+0 PCV10 schedule (2,3,4 months)
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: 2+1 PCV10 schedule (2,4,9.5 months)
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Two-dose PCV10 schedule (2,6 months)
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Control group (no infant doses of PCV)
Number of subjects: 1049
Study: 36785996

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 494

Group type: COMPARATOR
Intervention: Overall
Number of subjects: 494
Study: 36786049

Group type: EXPERIMENTAL
Intervention: Changing infusion set every 0-4 days
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Never/rarely missing a bolus
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Timing insulin 10-15 min before meal
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Self-adjusting pump settings
Number of subjects: 770

Group type: COMPARATOR
Intervention: Health care professionals doing all adjustments
Number of subjects: 770
Study: 36786053

Group type: EXPERIMENTAL
Intervention: JNJ-73763989 (200 mg, single subcutaneous dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JNJ-56136379 (250 mg, oral, single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JNJ-73763989 and JNJ-56136379
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Number of subjects: 0
Study: 36786322

Group type: EXPERIMENTAL
Intervention: Medication-overuse headache patients
Number of subjects: 120

Group type: COMPARATOR
Intervention: Controls (episodic migraine patients and healthy controls)
Number of subjects: 120
Study: 36786394

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) of M1
Number of subjects: 35
Study: 36786515

Group type: EXPERIMENTAL
Intervention: POLARx cryoballoon intervention
Number of subjects: 399
Study: 36786565

Group type: EXPERIMENTAL
Intervention: Restorative neurostimulation (ReActiv8)
Number of subjects: 146
Study: 36787013

Group type: EXPERIMENTAL
Intervention: Optimal medical management plus ReActiv8® restorative neurostimulation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 0
Study: 36787089

Group type: EXPERIMENTAL
Intervention: INCB062079 15 mg twice daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: INCB062079 10 mg once daily
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: INCB062079
Number of subjects: 23
Study: 36787124

Group type: EXPERIMENTAL
Intervention: Combination of diuretics with varying pharmacological targets for diuretic resistance and sodium avidity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invasive decongestion methods including ultrafiltration or kidney replacement therapy (KRT) such as peritoneal dialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies for increasing forward perfusion in low cardiac output and cardiogenic shock
Number of subjects: 0
Study: 36787125

Group type: COMPARATOR
Intervention: Assistance
Number of subjects: 4517

Group type: COMPARATOR
Intervention: Assistance with Surveillance
Number of subjects: 4517

Group type: COMPARATOR
Intervention: Collaborative
Number of subjects: 4517

Group type: COMPARATOR
Intervention: Collaborative with Surveillance
Number of subjects: 4517
Study: 36787165

Group type: EXPERIMENTAL
Intervention: mHealth-supported patient navigation for 12 months
Number of subjects: 450

Group type: COMPARATOR
Intervention: Standard of care patient support
Number of subjects: 450
Study: 36787172

Group type: EXPERIMENTAL
Intervention: SiS smartphone app
Number of subjects: 225

Group type: COMPARATOR
Intervention: QuitGuide smartphone app
Number of subjects: 225

Group type: COMPARATOR
Intervention: Clearing the Air brochure
Number of subjects: 225
Study: 36787181

Group type: EXPERIMENTAL
Intervention: REsOluTioN program (Resilience Enhancement Online Training for Nurses)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 93
Study: 36787235

Group type: EXPERIMENTAL
Intervention: Mindfulness-based music therapy intervention (4 sessions, 45 minutes each over 12 weeks)
Number of subjects: 31
Study: 36787249

Group type: EXPERIMENTAL
Intervention: Mosaic vaccine
Number of subjects: 105

Group type: COMPARATOR
Intervention: CON-S vaccine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Nat-B vaccine
Number of subjects: 105
Study: 36787296

Group type: EXPERIMENTAL
Intervention: Clinic-based SAMBA II assay
Number of subjects: 390

Group type: COMPARATOR
Intervention: Standard of care (SOC) VL monitoring at provincial referral laboratory (PRL)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Standard of care (SOC) VL monitoring at PRL
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 390
Study: 36787305

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/day orally for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 40
Study: 36787455

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36787512

Group type: EXPERIMENTAL
Intervention: Phone-based tailored risk counseling and navigation intervention (TCN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mailed targeted print education (TP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 36787524

Group type: EXPERIMENTAL
Intervention: SCS-TA (Xipere®; Bausch + Lomb) administered via the SCS Microinjector®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCS-TA (Xipere®; Bausch + Lomb)
Number of subjects: 0
Study: 36787525

Group type: EXPERIMENTAL
Intervention: Estradiol cream 50 μg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Estradiol cream 100 μg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Silicone lubricant (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups combined (estradiol and silicone lubricant)
Number of subjects: 50
Study: 36787527

Group type: EXPERIMENTAL
Intervention: German Day-to-Day Impact of Vaginal Aging (DIVA) questionnaire
Number of subjects: 121
Study: 36787645

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36787802

Group type: EXPERIMENTAL
Intervention: Follow-up at 6 months post COVID-19
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Follow-up at 12 months post COVID-19
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Baseline assessment
Number of subjects: 536
Study: 36787836

Group type: EXPERIMENTAL
Intervention: Non-granular (NG)-LNPCPs
Number of subjects: 3381

Group type: COMPARATOR
Intervention: Solitary LNPCPs
Number of subjects: 3381

Group type: EXPERIMENTAL
Intervention: Dominant LNPCPs in patients with multiple LNPCPs
Number of subjects: 3381
Study: 36787969

Group type: EXPERIMENTAL
Intervention: Pulmonary artery compliance (PAC)
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Resistance-compliance (RC) time
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: RC time in CTD-PAH
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: PAC
Number of subjects: 616
Study: 36787971

Group type: EXPERIMENTAL
Intervention: EOS calculator
Number of subjects: 1830

Group type: COMPARATOR
Intervention: Dutch guideline
Number of subjects: 1830
Study: 36787974

Group type: EXPERIMENTAL
Intervention: High nCPAP (positive end-expiratory pressure 9-15 cmH2O)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NIPPV (target mean Paw 9-15 cmH2O)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High nCPAP or NIPPV
Number of subjects: 0
Study: 36788015

Group type: EXPERIMENTAL
Intervention: Model 1 (includes 4-Hydroxy-3-methoxyphenylglycol sulfate, galacturonic acid, hexanoylcarnitine, and age)
Number of subjects: 1682

Group type: EXPERIMENTAL
Intervention: Model 2 (includes 4-Hydroxy-3-methoxyphenylglycol sulfate, hexanoylcarnitine, bilirubin, INR, and age)
Number of subjects: 1682

Group type: EXPERIMENTAL
Intervention: Model 1
Number of subjects: 1682

Group type: EXPERIMENTAL
Intervention: Model 2
Number of subjects: 1682

Group type: EXPERIMENTAL
Intervention: Models including metabolites (CLIF-C MET)
Number of subjects: 1682
Study: 36788081

Group type: EXPERIMENTAL
Intervention: Short-term preoperative endocrine therapy (pET; tamoxifen or aromatase inhibitor)
Number of subjects: 364
Study: 36788198

Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Straight blade videolaryngoscopy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hyperangulated videolaryngoscopy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Videolaryngoscopy (both types)
Number of subjects: 30
Study: 36788215

Group type: EXPERIMENTAL
Intervention: Improved water, sanitation and hygiene (WASH) and infant and young child feeding (IYCF) interventions
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Maternal HIV infection
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Functional metagenomic features
Number of subjects: 335
Study: 36788482

Group type: EXPERIMENTAL
Intervention: High-frequency training (3 times a week for 12 weeks)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Low-frequency training (1 time a week for 12 weeks)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both HF and LF groups
Number of subjects: 89
Study: 36788511

Group type: EXPERIMENTAL
Intervention: Topical TAC 0.1% patch twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Topical TAC 0.1% gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical TRI 0.1% gel four times daily
Number of subjects: 30
Study: 36788520

Group type: EXPERIMENTAL
Intervention: AstroRx® (100 × 10^6 cells)
Number of subjects: 5
Study: 36788619

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 32
Study: 36788652

Group type: EXPERIMENTAL
Intervention: Dysfunctional Lens Index (DLI)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: LOCS III
Number of subjects: 106
Study: 36789426

Group type: EXPERIMENTAL
Intervention: Virtual reality intervention targeting distress and anxiety symptoms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36789481

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 999

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 999
Study: 36789515

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/day
Number of subjects: 751

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Cariprazine 3.0 mg/day
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/day and 3.0 mg/day
Number of subjects: 751
Study: 36789577

Group type: EXPERIMENTAL
Intervention: Fexuprazan 20 mg once a day (q.d.)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Fexuprazan 10 mg twice a day (b.i.d.)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study: 36789614

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Antiplatelet agent
Number of subjects: 306

Group type: COMPARATOR
Intervention: Hospitalisation
Number of subjects: 306

Group type: COMPARATOR
Intervention: Age
Number of subjects: 306

Group type: COMPARATOR
Intervention: Haemoglobin level
Number of subjects: 306

Group type: COMPARATOR
Intervention: Oral anticoagulant vs. antiplatelet agent
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Thrombotic events
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Bleeding events
Number of subjects: 306
Study: 36789773

Group type: EXPERIMENTAL
Intervention: Ticagrelor-aspirin
Number of subjects: 4168

Group type: COMPARATOR
Intervention: Clopidogrel-aspirin
Number of subjects: 4168
Study: 36789835

Group type: EXPERIMENTAL
Intervention: Moderate-to-high burden PVC group (≥1000/day)
Number of subjects: 16030

Group type: COMPARATOR
Intervention: Low burden PVC group (<1000/day)
Number of subjects: 16030
Study: 36789931

Group type: EXPERIMENTAL
Intervention: Circulating miR-128-1-5p levels
Number of subjects: 495
Study: 36789941

Group type: EXPERIMENTAL
Intervention: Garlic vegetable intake
Number of subjects: 3229

Group type: EXPERIMENTAL
Intervention: Scallion intake
Number of subjects: 3229

Group type: EXPERIMENTAL
Intervention: Total allium vegetable intake
Number of subjects: 3229

Group type: EXPERIMENTAL
Intervention: Combined prevalence of dysplasia or GC
Number of subjects: 3229
Study: 36789945

Group type: EXPERIMENTAL
Intervention: FeFum+GOS (5.0 mg iron with 3.0 g GOS)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: FeFum+HMO (5.0 mg iron with 3.0 g HMO)
Number of subjects: 55

Group type: COMPARATOR
Intervention: FeFum (5.0 mg iron without GOS or HMO)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: FeFum+GOS
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: FeFum+HMO
Number of subjects: 55
Study: 36789947

Group type: EXPERIMENTAL
Intervention: Short breastfeeding (≤4 months)
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Early complementary feeding (≤4 months)
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: Early CF and short BF
Number of subjects: 839

Group type: COMPARATOR
Intervention: Early CF-long BF
Number of subjects: 839
Study: 36789976

Group type: EXPERIMENTAL
Intervention: Lesion-to-fat ratio measured by shear wave elastography
Number of subjects: 1288

Group type: COMPARATOR
Intervention: Conventional B-mode ultrasound
Number of subjects: 1288
Study: 36790041

Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg once daily (induction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily (maintenance)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg once daily (maintenance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (induction and maintenance)
Number of subjects: 0
Study: 36790138

Group type: EXPERIMENTAL
Intervention: Myo-inositol supplementation
Number of subjects: 1319
Study: 36790141

Group type: EXPERIMENTAL
Intervention: DM1
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: DM2
Number of subjects: 185

Group type: COMPARATOR
Intervention: Non-DM muscular dystrophy cohort
Number of subjects: 185
Study: 36790337

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR)
Number of subjects: 57
Study: 36790457

Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Parity (1 child)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Parity (≥ 2 children)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: High intake of total meat (≥ 108.57 g/day)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: High intake of red/processed meat (≥ 74.29 g/day)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: High intake of protein (≥ 65.05 g/day)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: High intake of dietary iron (≥ 8.58 mg/day)
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 791
Study: 36790588

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentrations of GFAP, NSE, IFN-γ, TNF-α, IL-2, IL-12p70, IL-4, IL-10, and IL-13
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Peripheral blood (PB) concentrations of GFAP and IFN-γ
Number of subjects: 15

Group type: COMPARATOR
Intervention: Cerebrospinal fluid (CSF) and peripheral blood (PB) biomarker concentrations
Number of subjects: 15
Study: 36790596

Group type: EXPERIMENTAL
Intervention: 1000 mg metformin with 10 mg baxdrostat
Number of subjects: 27

Group type: COMPARATOR
Intervention: 1000 mg metformin alone
Number of subjects: 27
Study: 36790672

Group type: EXPERIMENTAL
Intervention: Low-level red-light (RLRL) therapy
Number of subjects: 264

Group type: COMPARATOR
Intervention: Single vision spectacle (SVS)
Number of subjects: 264
Study: 36790808

Group type: EXPERIMENTAL
Intervention: Laparoscopic Proximal Gastrectomy with Double-Tract Reconstruction (LPG-DTR)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Laparoscopic Total Gastrectomy (LTG)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: LPG-DTR
Number of subjects: 138

Group type: COMPARATOR
Intervention: LTG
Number of subjects: 138
Study: 36790846

Group type: EXPERIMENTAL
Intervention: mHealth intervention consisting of sending messages through a multimedia messaging service with food education for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 0
Study: 36790849

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36790852

Group type: EXPERIMENTAL
Intervention: VR (Virtual Reality)
Number of subjects: 126

Group type: COMPARATOR
Intervention: MEOPA (mixture of nitrous oxide/oxygen)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: VR
Number of subjects: 126
Study: 36790875

Group type: EXPERIMENTAL
Intervention: Glucose Management Indicator (GMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycated Hemoglobin (HbA1c)
Number of subjects: 0
Study: 36790881

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36790946

Group type: EXPERIMENTAL
Intervention: Yogic Breathing (YB) via app for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Attention Control (AC) via app for 12 weeks
Number of subjects: 20
Study: 36791089

Group type: EXPERIMENTAL
Intervention: Self-applied treatment for rat phobia supported by a Virtual Therapy Assistant (VTA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 45